Montelukast Use in Infants

Dosing and Administration

• The appropriate dose of montelukast for a 10-month-old infant is 4-mg oral granules administered once daily, as recommended by medical guidelines 1

Safety Considerations

• The FDA issued a black box warning regarding serious neuropsychiatric events with montelukast, including suicidal thoughts and actions, depression, anxiety, sleep disturbances, and behavioral changes, as reported in the American Journal of Respiratory and Critical Care Medicine 2
• Before prescribing montelukast to any child, parents must be explicitly counseled about neuropsychiatric risks, including the potential for behavioral changes, and safer alternatives should be considered, according to medical guidelines 3, 4
• Monitoring for unusual behavioral or mood changes is required, particularly in the first weeks of therapy, as recommended by medical guidelines 3, 4

Adverse Events

• Common adverse events (≥2% frequency, more than placebo) in infants 6-23 months of age include upper respiratory infection, wheezing, otitis media, pharyngitis, tonsillitis, cough, and rhinitis, as reported in the American Journal of Respiratory and Critical Care Medicine 2

Montelukast in Infants

Introduction to Montelukast

• Montelukast can be given to a 6-month-old infant, as it has FDA approval and guideline support down to 6 months of age for asthma and allergic rhinitis, but only after careful consideration of the FDA black box warning regarding neuropsychiatric risks and discussion of safer alternatives with parents 5

FDA-Approved Age and Dosing

• Montelukast is FDA-approved down to 6 months of age with an excellent safety profile according to guideline recommendations 5

Clinical Context and Positioning

• For patients with both asthma and allergic rhinitis, montelukast may offer dual benefit since it is approved for both conditions 5
• The American Academy of Allergy, Asthma, and Immunology recommends montelukast as an alternative therapy for mild persistent asthma when inhaled corticosteroids are not tolerated or compliance is an issue, although this specific recommendation is not directly cited, the general use of montelukast in this context is supported by the FDA approval and guideline support down to 6 months of age for asthma and allergic rhinitis 5

Montelukast Therapy in Infants

Clinical Context and Positioning

• The American Academy of Family Physicians recommends considering montelukast as an alternative therapy for mild persistent asthma when inhaled corticosteroids cannot be used or compliance is problematic, due to its once-daily oral administration offering superior compliance compared to inhaled therapies 6, 7
• The American Academy of Family Physicians advises against using montelukast for acute asthma exacerbations or rescue therapy, and recommends ensuring parents have a short-acting beta-agonist available for acute symptoms 6

Montelukast Dosing and Administration

Age-Specific Dosing Recommendations

• The American Academy of Family Physicians and the American Academy of Allergy, Asthma, and Immunology recommend 4 mg chewable tablet once daily for preschool children (2 to 5 years) 8, 9
• The American Academy of Family Physicians and the American Academy of Allergy, Asthma, and Immunology recommend 5 mg chewable tablet once daily for school-age children (6 to 14 years) 8, 9

Clinical Positioning

• The American Academy of Family Physicians recommends montelukast as an alternative therapy for mild persistent asthma when inhaled corticosteroids cannot be used or compliance is problematic 8
• The American Academy of Family Physicians suggests combining montelukast with inhaled corticosteroids as an alternative to long-acting beta agonists for moderate persistent asthma, though less preferred 8

Montelukast Therapy in Pediatric Patients

Introduction to Montelukast Therapy

• The American Academy of Allergy, Asthma, and Immunology recommends that montelukast should not be used as monotherapy for moderate-to-severe persistent asthma, as inhaled corticosteroids are superior for asthma control 10

Comparative Efficacy of Montelukast

• Inhaled corticosteroids, such as fluticasone, are superior to montelukast for asthma control days and all control outcomes in children with mild-to-moderate persistent asthma, with a number needed to treat (NNT) of approximately 6.5 10

Montelukast Prescribing Guidelines for Children

Introduction to Montelukast Therapy

• The American Academy of Allergy, Asthma, and Immunology recommends montelukast as an alternative therapy for mild persistent asthma in children, although inhaled corticosteroids are preferred 11
• Montelukast can be used as adjunctive therapy with inhaled corticosteroids for moderate persistent asthma in children, but is not the preferred add-on therapy compared to long-acting beta-agonists in patients ≥12 years 11

Age-Specific Indications

• The FDA approves montelukast for perennial allergic rhinitis in children as young as 6 months of age, and for seasonal allergic rhinitis in children as young as 2 years of age 12, 13
• Clinical evidence supports the use of montelukast for exercise-induced asthma in children as young as 6 years 11

Clinical Context for Use

• Montelukast offers advantages in treating children with dual upper and lower airway disease, as it addresses both asthma and allergic rhinitis simultaneously 12, 13
• Montelukast can be considered for children with compliance issues or steroid-phobic parents, as it provides an alternative to inhaled corticosteroids 12, 13

Onset of Action and Treatment Duration

• The onset of action of montelukast occurs by the second day of daily treatment, and it must be taken continuously daily to maintain efficacy 13, 14

Montelukast Clinical Evidence and Comparative Effectiveness

Dose Selection and Pharmacodynamics

• In adults and adolescents (≥ 15 years), the 10 mg once‑daily tablet was chosen because dose‑ranging studies demonstrated a flat dose‑response curve, with doses > 10 mg providing no additional efficacy. 15
• For school‑age children (6–14 years), a 5 mg chewable tablet yields systemic exposure that is comparable to the 10 mg adult dose, supporting its use for asthma and allergic rhinitis. 16

Administration Timing

• Montelukast can be taken at any time of day, but evening dosing is the traditional practice for the once‑daily regimen. 15

Comparative Effectiveness in Asthma Management

• Montelukast is not a first‑line therapy for asthma; inhaled corticosteroids (ICS) are superior for children with mild‑to‑moderate persistent asthma, with a number needed to treat (NNT) of approximately 6.5. 16
• When used as add‑on therapy to ICS, montelukast is less effective than long‑acting β‑agonists (LABA) in improving asthma control. 16
• In school‑age children, montelukast has demonstrated efficacy for both asthma control and allergic rhinitis, providing a dual‑indication advantage. 16

Exercise‑Induced Bronchospasm

• Montelukast may attenuate exercise‑induced bronchospasm, but its effect is inferior to that of inhaled corticosteroid therapy. 15

Allergic Rhinitis Management: Recommendations for Montelukast

First‑Line Therapy Preference

• The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines strongly recommend intranasal corticosteroids as the first‑line treatment for both seasonal and persistent allergic rhinitis, indicating they are superior to montelukast. This is a strong recommendation based on comparative efficacy data. 17

Preferred Alternatives to Montelukast

• According to the ARIA guidelines, intranasal corticosteroids are preferred over oral leukotriene receptor antagonists (e.g., montelukast) for seasonal allergic rhinitis. The guideline provides a strong recommendation reflecting higher symptom control. 17
• The same guidelines state that oral H1‑antihistamines are also preferred to montelukast for seasonal allergic rhinitis, reflecting a strong recommendation for antihistamines as a more effective option. 17

Conditional Use in Specific Pediatric Population

• For preschool children with persistent allergic rhinitis, the ARIA guidelines issue a conditional recommendation to consider montelukast when other first‑line options are unsuitable or not tolerated. This reflects limited evidence and a need for individualized decision‑making. 17